Skip to main content
Premium Trial:

Request an Annual Quote

Massachusetts Gov. Deval Patrick, Mark Collar, John Benassi, Chris Neugebauer

After Signing $1B Biobill, Massachusetts’ Deval Patrick Honored as ‘Governor of the Year’
Massachusetts Gov. Deval Patrick was named Governor of the Year by the Biotechnology Industry Organization on June 17, a day after he signed a $1 billion, 10-year package of economic incentives intended to enhance the top-tier status of his state’s life sciences industry.
Patrick was honored “in recognition of his leadership and support of the biosciences industry,” BIO stated in its announcement of the award. He received his award during a keynote luncheon at the BIO 2008 International Convention, held in San Diego.
"The Governor has demonstrated unflinching dedication to our state's tradition as a welcoming home to research institutions and companies dedicated to combating the diseases that plague mankind. The signing of the Massachusetts Life Science Initiative is yet another example of the comprehensive approach Governor Patrick and his staff take to ensure the long-term success of the life sciences in Massachusetts,” Joshua Boger, chairman of BIO’s board of directors and president and CEO of Vertex Pharmaceuticals, said in the announcement.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the US and more than 30 nations.

Retired P&G Executive Joins Triathlon Medical Ventures as Venture Partner
Mark Collar has joined Triathlon Medical Ventures as a venture partner. Triathlon is a Cincinnati-based Midwestern venture capital firm that invests exclusively in the life sciences.
Collar retired last year as president of Procter & Gamble's global pharmaceuticals and personal health division. 
Collar began his career at P&G in 1975 as a sales representative, and advanced through positions of increased responsibility to the pharmaceuticals division in 1994, becoming president of global pharmaceuticals in 2002, and assuming additional responsibility for P&G’s global personal health business three years later.
Collar currently is chairman of the Third Frontier Advisory Board, which provides direction for Ohio's $1.6 billion economic development investment fund, through appointment by Gov. Ted Strickland. He is also vice chairman of BioOhio, the state’s life sciences industry group. Collar was recently named to the board of directors of Ohio-based AtriCure, a publicly traded medical device company, and also serves on the research committee of the board of trustees for Cincinnati Children's Hospital.
A native of Wisconsin, Collar resides with his family in Cincinnati.

Heller Ehrman IP Lawyer Bolts for Cooley Godward Kronish
John Benassi has joined the San Diego office of the law firm Cooley Godward Kronish as a partner in its intellectual property practice group. He joined the firm from the San Diego office of Heller Ehrman.
Benassi's practice will continue to focus on patent matters, specifically cases involving ANDA, medical device litigation — as well as other IP litigation involving software, wireless, video compression, encryption, and communications technology.
Benassi will join former Heller partner and IP litigator Jessica Wolff, who moved to the Cooley law firm last week, in an expansion of its IP litigation practice.
Benassi has represented biotech, medical device, and other high-tech clients in state and federal trials over 28 years. He earned a BS in Engineering from the University of Illinois in 1971, and was awarded his JD cum laude from George Washington University School of Law in 1974. He clerked in the trial division of the US Claims Court, assisting in the trial and decision of patent infringement cases brought against the US Government. He is admitted to practice before the Patent and Trademark Office.

Diversified Project Management Hires Chris Neugebauer as Senior Project Manager
Chris Neugebauer has been hired as a senior project manager by Diversified Project Management, an independent owner's representative consulting company. Neugebauer will work from DPM's headquarters in Newton, Mass.
He previously served as project manager for Beverly Hospital Design and Construction, where he supervised contractors, architects, engineers, interior designers, furniture representatives and associated vendors through various phases of design, construction, occupancy and project delivery, and carried out duties that included schedule compliance, construction quality, expenditure approval and reporting to management. 
Neugebauer also served as project manager for Bauer Architectural Design and Builders, project manager for the Museum of Fine Arts Boston, project manager for Harvard Business School, planning and construction; project architect/planner for Brigham & Women's Hospital; and a project administration/space planner, and interior architect for Shepley Bulfinch Richardson/Abbott Architects.
Neugebauer is a graduate of the Boston Architectural Center, where he also serves as a studio design instructor.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.